關(guān)鍵詞

單克隆抗體 癌癥免疫 巨噬細(xì)胞 來那替尼 舒馬曲坦 伊奈利珠單抗 司庫奇尤單抗 維迪西妥單抗 特瑞普利單抗 帕博利珠單抗

?

#今日行業(yè)熱點(diǎn)#

①The Lancet Haematology：Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies

在抗CD38單克隆抗體背景下，自體造血細(xì)胞移植(HDM-AHCT)在系統(tǒng)性輕鏈型淀粉樣變性治療中的作用

DOI: 10.1016/S2352-3026(23)00175-8

②Molecular Cancer：Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

綜述：定義腫瘤微環(huán)境中的癌癥相關(guān)成纖維細(xì)胞(CAFs):癌癥免疫治療的新機(jī)遇和臨床試驗(yàn)的進(jìn)展

DOI: 10.1186/s12943-023-01860-5

③Cancer Immunology, Immunotherapy：Tumor-associated macrophages as a potential therapeutic target in thyroid cancers

腫瘤相關(guān)巨噬細(xì)胞作為甲狀腺癌的潛在治療靶點(diǎn)

DOI: 10.1007/s00262-023-03549-6

④Molecular Medicine：Neratinib for HER2-positive breast cancer with an overlooked option

被忽視的選擇——酪氨酸激酶抑制劑來那替尼(Neratinib)在人表皮生長因子受體2 (HER2)陽性乳腺癌中的應(yīng)用

DOI: 10.1186/s10020-023-00736-0

⑤Diabetes Obesity and Metabolism：Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double-blinded placebo-controlled cross-over trial

高度選擇性5- 羥色胺受體（5-HT）激動(dòng)劑舒馬曲坦（Sumatriptan）用于急性降低超重人群的胰島素分泌、敏感性和葡萄糖有效性：一項(xiàng)雙盲安慰劑對照交叉試驗(yàn)

DOI: 10.1111/dom.15176

⑥Annals of Clinical and Translational Neurology：Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes

人源化CD19導(dǎo)向性單克隆抗體伊奈利珠單抗（Inebilizumab）可降低獨(dú)立于FCGR3A多態(tài)性的視神經(jīng)脊髓炎譜系障礙風(fēng)險(xiǎn)

DOI: 10.1002/acn3.51911

⑦IL-17A單抗司庫奇尤單抗（Secukinumab）靜脈注射劑獲FDA批準(zhǔn)上市，用于成人銀屑病關(guān)節(jié)炎（PsA）、強(qiáng)直性脊柱炎（AS）和非放射學(xué)中軸型脊柱關(guān)節(jié)炎（nr-axSpA）

⑧雙重M1/M4毒蕈堿乙酰膽堿受體激動(dòng)劑KarXT (xanomeline-trospium) 在美申報(bào)上市，用于精神分裂癥和阿爾茨海默癥導(dǎo)致的精神病

⑨首個(gè)國產(chǎn)ADC藥物維迪西妥單抗聯(lián)合特瑞普利單抗和鉑類藥物用于可切除胃癌/胃食管結(jié)合部腺癌的Ⅱ期臨床研究獲中國國家藥品監(jiān)督管理局藥品審評中心（CDE）批準(zhǔn)

⑩帕博利珠單抗（Keytruda）輔助用于局部肌層浸潤性尿路上皮癌（MIUC）和局部晚期尿路上皮癌（UC）的III期KEYNOTE-123研究達(dá)到無病生存期（DFS）主要終點(diǎn)

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！